These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35780655)

  • 1. Synthesis and biological evaluation of a tumor-selective degrader of PARP1.
    Pu C; Wang S; Luo D; Liu Y; Ma X; Zhang H; Yu S; Lan S; Huang Q; Deng R; He X; Li R
    Bioorg Med Chem; 2022 Sep; 69():116908. PubMed ID: 35780655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer.
    Li G; Lin SS; Yu ZL; Wu XH; Liu JW; Tu GH; Liu QY; Tang YL; Jiang QN; Xu JH; Huang QL; Wu LX
    Biochem Pharmacol; 2022 Dec; 206():115329. PubMed ID: 36309080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective degradation of PARP2 by PROTACs via recruiting DCAF16 for triple-negative breast cancer.
    Pu C; Tong Y; Liu Y; Lan S; Wang S; Yan G; Zhang H; Luo D; Ma X; Yu S; Huang Q; Deng R; Li R
    Eur J Med Chem; 2022 Jun; 236():114321. PubMed ID: 35430559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1).
    Zhang Z; Chang X; Zhang C; Zeng S; Liang M; Ma Z; Wang Z; Huang W; Shen Z
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1606-1615. PubMed ID: 32779949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly(ADP-ribosyl)ation of BRD7 by PARP1 confers resistance to DNA-damaging chemotherapeutic agents.
    Hu K; Wu W; Li Y; Lin L; Chen D; Yan H; Xiao X; Chen H; Chen Z; Zhang Y; Xu S; Guo Y; Koeffler HP; Song E; Yin D
    EMBO Rep; 2019 May; 20(5):. PubMed ID: 30940648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a potent and selective PARP1 degrader promoting cell cycle arrest via intercepting CDC25C-CDK1 axis for treating triple-negative breast cancer.
    Wu Y; Wu M; Zheng X; Yu H; Mao X; Jin Y; Wang Y; Pang A; Zhang J; Zeng S; Xu T; Chen Y; Zhang B; Lin N; Dai H; Wang Y; Yao X; Dong X; Huang W; Che J
    Bioorg Chem; 2024 Jan; 142():106952. PubMed ID: 37952486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly(ADP‑ribose) polymerase 1/2 inhibitors decrease the ubiquitination of ALC1 mediated by CHFR in breast cancer.
    Wang Y; Wang Y; Wang N; You L; Long F; Shao C; Wang Y; Wu J
    Oncol Rep; 2019 Oct; 42(4):1467-1474. PubMed ID: 31322269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy.
    Peng X; Pan W; Jiang F; Chen W; Qi Z; Peng W; Chen J
    Pharmacol Res; 2022 Dec; 186():106529. PubMed ID: 36328301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency.
    Gatti M; Imhof R; Huang Q; Baudis M; Altmeyer M
    Cell Rep; 2020 Aug; 32(5):107985. PubMed ID: 32755579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers.
    Cao C; Yang J; Chen Y; Zhou P; Wang Y; Du W; Zhao L; Chen Y
    J Med Chem; 2020 Oct; 63(19):11012-11033. PubMed ID: 32924477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CHFR-mediated degradation of RNF126 confers sensitivity to PARP inhibitors in triple-negative breast cancer cells.
    Wu W; Zhao J; Xiao J; Wu W; Xie L; Xie X; Yang C; Yin D; Hu K
    Biochem Biophys Res Commun; 2021 Oct; 573():62-68. PubMed ID: 34388456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor.
    Niu T; Li K; Jiang L; Zhou Z; Hong J; Chen X; Dong X; He Q; Cao J; Yang B; Zhu CL
    Eur J Med Chem; 2022 Jan; 228():114012. PubMed ID: 34864331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines.
    Pierce A; McGowan PM; Cotter M; Mullooly M; O'Donovan N; Rani S; O'Driscoll L; Crown J; Duffy MJ
    Cancer Biol Ther; 2013 Jun; 14(6):537-45. PubMed ID: 23760496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High affinity and low PARP-trapping benzimidazole derivatives as a potential warhead for PARP1 degraders.
    Peng X; Li Y; Qu J; Jiang L; Wu K; Liu D; Chen Y; Peng J; Guo Y; Cao X
    Eur J Med Chem; 2024 May; 271():116405. PubMed ID: 38678823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule.
    Zhao Q; Lan T; Su S; Rao Y
    Chem Commun (Camb); 2019 Jan; 55(3):369-372. PubMed ID: 30540295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP.
    Zheng M; Huo J; Gu X; Wang Y; Wu C; Zhang Q; Wang W; Liu Y; Liu Y; Zhou X; Chen L; Zhou Y; Li H
    J Med Chem; 2021 Jun; 64(11):7839-7852. PubMed ID: 34038131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
    Du Y; Yamaguchi H; Wei Y; Hsu JL; Wang HL; Hsu YH; Lin WC; Yu WH; Leonard PG; Lee GR; Chen MK; Nakai K; Hsu MC; Chen CT; Sun Y; Wu Y; Chang WC; Huang WC; Liu CL; Chang YC; Chen CH; Park M; Jones P; Hortobagyi GN; Hung MC
    Nat Med; 2016 Feb; 22(2):194-201. PubMed ID: 26779812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of novel dual target inhibitors of PARP and EGFR and their antitumor activities in triple negative breast cancers.
    Lin S; Zhang X; Yu Z; Huang X; Xu J; Liu Y; Wu L
    Bioorg Med Chem; 2022 May; 61():116739. PubMed ID: 35393219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.